Printer Friendly

BIODYNAMICS THIRD QUARTER REVENUES UP 74 PERCENT

 TAMPA, Fla., Oct. 15 /PRNewswire/ -- Biodynamics International, Inc. (NASDAQ: BDYN) today reported revenues for the third fiscal quarter ended Aug. 31, of $3,483,816 up from $2,003,703 for the same period last year, an increase of 74 percent. The company reported a net loss of $362,303 or $.05 per share for the current quarter as compared to net income of $128,000 or $.03 per share for the third quarter of 1992. The net loss for the quarter includes non-cash items of $461,635 primarily attributable to the recent German acquisition. Gross margin improved significantly for the quarter from 46 percent in 1992 to 62 percent in 1993. Higher margins are attributable to the effect of combined margins related to U.S. and German operations and the generally higher margins of the German subsidiary.
 Revenues for the nine months ended Aug. 31, increased by 36 percent to $6,655,694 compared to $4,901,856 reported for the same period of 1992. The net loss for the period was $1,069,164, or $.14 per share compared to net income of $490,024, or $.04 per share for the nine months of 1992.
 Commenting on the results, Biodynamics President John V. Hargiss stated, "The 74 percent increase in revenues has come about as a result of the consolidation of internationally derived revenues generated from the company's German subsidiary. We continue to make progress in our previously stated objective of improving all aspects of our processing operations and steps taken to date should accelerate this process during the next three months."
 Biodynamics International, Inc. processes, manufactures and distributes worldwide, specialty surgical products for neuro, orthopedic, cardiovascular, reconstructive and general surgical applications. The company is headquartered in Tampa. The company's wholly owned subsidiary, Biodynamics International (Deutschland) GmbH, has processing and manufacturing facilities in Neunkirchen, Germany and executive offices in Erlangen, Germany.
 BIODYNAMICS INTERNATIONAL, INC. AND SUBSIDIARIES
 CONSOLIDATED FINANCIAL SUMMARY
 (unaudited)
 Three Months Ended
 Aug. 31,
 1993 1992
 REVENUES $3,483,816 $2,003,703
 Gross Margin 2,161,890 912,062
 Operating expenses (1,630,440) (509,889)
 Depreciation, amortization and
 non-cash items (461,635) (26,117)
 Loss in equity investment and
 minority interest (126,298) (158,774)
 Other income and expense (305,820) (88,394)
 Net income (loss) $ (362,303) $ 128,888
 Earnings (loss) per share $ (0.05) $ 0.03
 Nine Months Ended
 Aug. 31,
 1993 1992
 REVENUES $6,655,694 $4,901,856
 Gross Margin 3,705,319 2,389,980
 Operating expenses (3,010,409) (1,465,306)
 Depreciation, amortization and
 non-cash items (992,844) (70,947)
 Loss in equity investment and
 minority interest (341,454) (255,492)
 Other income and expense (429,776) (108,211)
 Net income (loss) $(1,069,164) $ 490,024
 Earnings (loss) per share $ (0.14) $ 0.04
 CONDENSED CONSOLIDATED BALANCE SHEETS
 Aug. 31, Nov. 30,
 1993 1992
 (unaudited) (audited)
 Current assets $ 6,113,345 $ 2,274,201
 Fixed assets 3,681,565 154,481
 Other assets 10,343,543 1,716,943
 Total assets $20,138,453 $ 4,145,625
 Current liabilities $ 2,568,944 $ 963,870
 Long-term liabilities 15,719,155 207,171
 Shareholders' equity 1,850,354 2,974,584
 Total liabilities &
 shareholders' equity $20,138,453 $ 4,145,625
 -0- 10/14/93
 /CONTACT: Robert Sicignano of Biodynamics International, 813-921-0556/
 (BDYN)


CO: Biodynamics International, Inc. ST: Florida IN: MTC SU: ERN

JV-AW -- FL004 -- 2682 10/15/93 11:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1993
Words:573
Previous Article:CITIZENS BANKING CORPORATION DECLARES DIVIDEND
Next Article:DIODES ANNOUNCES RECORD THIRD QUARTER REVENUES; POISED FOR MOST SUCCESSFUL YEAR TO DATE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters